keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/27927740/chronic-vortioxetine-treatment-reduces-exaggerated-expression-of-conditioned-fear-memory-and-restores-active-coping-behavior-in-chronically-stressed-rats
#1
Lauren Hatherall, Connie Sánchez, David A Morilak
BACKGROUND: Stress is a risk factor for depression and anxiety disorders, disrupting neuronal processes leading to exaggerated fear and compromised coping behaviors. Current antidepressants are only partially effective. Vortioxetine, a novel multimodal antidepressant, is a serotonin transporter (SERT) inhibitor, 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B partial agonist, and 5-HT1A agonist. We have shown that chronic dietary vortioxetine administration reversed stress-induced deficits in cognitive flexibility...
December 7, 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27869048/efficacy-safety-and-tolerability-of-vortioxetine-for-the-treatment-of-major-depressive-disorder-in-patients-aged-55-years-or-older
#2
George G Nomikos, Dapo Tomori, Wei Zhong, John Affinito, William Palo
OBJECTIVE: These post hoc analyses evaluate the efficacy, safety, and tolerability of vortioxetine versus placebo in patients aged ≥55 years with major depressive disorder (MDD). METHODS: Study-level efficacy data from 12 short-term, fixed-dose, randomized, placebo-controlled trials of vortioxetine 5-20 mg/day were assessed using a random-effects meta-analysis. Adverse events (AEs), vital signs, ECG values, liver enzymes, and body weight were pooled from the same studies...
November 21, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27807822/vortioxetine-a-review-in-cognitive-dysfunction-in-depression
#3
James E Frampton
Vortioxetine (Brintellix(®); Trintellix(®)), a generally efficacious and well tolerated antidepressant agent, is approved in the EU and USA for the treatment of major depressive disorder (MDD) in adults. The drug has a distinctive pharmacological profile (combining inhibition of the serotonin transporter with modulation of multiple serotonin receptors) and has been shown to enhance cognitive performance in various animal models and clinical trials. Across three large, placebo-controlled studies in adults with recurrent MDD, short-term treatment with vortioxetine almost always resulted in statistically significant and clinically meaningful improvements in performance on two objective measures (the Digit Symbol Substitution Test and Rey Auditory Verbal Learning Test) that together cover a broad range of cognitive domains, including executive function, attention, processing speed, learning and memory...
November 2016: Drugs
https://www.readbyqxmd.com/read/27781949/current-and-future-perspectives-on-the-major-depressive-disorder-focus-on-the-new-multimodal-antidepressant-vortioxetine
#4
Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, Felice Iasevoli, Elisabetta Filomena Buonaguro, Michele Fornaro, Annastasia L C Fiengo, Giovanni Martinotti, Federica Vellante, Ilaria Matarazzo, Roberta Vecchiotti, Giampaolo Perna, Marco Di Nicola, Alessandro Carano, Andrea de Bartolomeis, Massimo Di Giannantonio, Domenico De Berardis
BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5¬HT) transporter inhibitor as well as 5¬HT3A and 5¬HT7 receptors antagonist, 5¬HT1A and 5¬HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD). OBJECTIVE: The present article aims at systematically reviewing findings of the published and unpublished research on the pharmacological properties, efficacy, safety and tolerability of oral VRX in the treatment of major depressive disorder (MDD)...
October 25, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27780334/efficacy-of-vortioxetine-on-cognitive-functioning-in-working-patients-with-major-depressive-disorder
#5
Roger S McIntyre, Ioana Florea, Brigitte Tonnoir, Henrik Loft, Raymond W Lam, Michael Cronquist Christensen
OBJECTIVE: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD). METHODS: Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ)...
October 25, 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27756833/the-frontal-cortex-as-a-network-hub-controlling-mood-and-cognition-probing-its-neurochemical-substrates-for-improved-therapy-of-psychiatric-and-neurological-disorders
#6
Mark J Millan, Jean-Michel Rivet, Alain Gobert
The highly-interconnected and neurochemically-rich frontal cortex plays a crucial role in the regulation of mood and cognition, domains disrupted in depression and other central nervous system disorders, and it is an important site of action for their therapeutic control. For improving our understanding of the function and dysfunction of the frontal cortex, and for identifying improved treatments, quantification of extracellular pools of neuromodulators by microdialysis in freely-moving rodents has proven indispensable...
October 17, 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27745932/systematic-review-of-randomized-controlled-trials-of-candidate-treatments-for-cognitive-impairment-in-depression-and-methodological-challenges-in-the-field
#7
REVIEW
K W Miskowiak, C V Ott, J Z Petersen, L V Kessing
Cognitive impairment is a core feature of Major Depressive Disorder (MDD) but treatments targeting cognition are lacking. Numerous pre-clinical and clinical studies have investigated potential cognition treatments, but overall the evidence is conflicting. We conducted a systematic search following the PRISMA guidelines on PubMed and PsychInfo to evaluate the extant evidence and methodological challenges in randomized controlled trials (RCTs) of biological, psychological and behavioural candidate treatments targeting cognition in MDD...
December 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27739610/mechanism-and-scope-of-base-controlled-catalyst-free-n-arylation-of-amines-with-unactivated-fluorobenzenes
#8
Christian Borch Jacobsen, Morten Meldal, Frederik Diness
A general method for transition metal-free N-arylation of amines has been developed. Mechanistic studies have revealed that the ability of the base to facilitate the desired amination without promoting unwanted side reactions is the guiding factor. By employing lithium bis(trimethylsilyl)amide as a base the resultant deprotonated amines readily react with a range of unactivated fluorobenzene derivatives. This new arylation method is utilized for the simple two-step synthesis of the antidepressant Vortioxetine...
October 14, 2016: Chemistry: a European Journal
https://www.readbyqxmd.com/read/27738380/treatment-resistant-depression-with-loss-of-antidepressant-response-rapid-acting-antidepressant-action-of-dextromethorphan-a-possible-treatment-bridging-molecule
#9
Edward C Lauterbach
Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.(1,2) This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a rapid-acting antidepressant effect within 48 hours of DM administration and lasting 7 days, sustained up to 20 days with daily administration, then gradually developing labile loss of antidepressant response over the ensuing 7 days...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27725683/a-randomized-placebo-controlled-active-reference-double-blind-flexible-dose-study-of-the-efficacy-of-vortioxetine-on-cognitive-function-in-major-depressive-disorder
#10
Atul R Mahableshwarkar, John Zajecka, William Jacobson, Yinzhong Chen, Richard Se Keefe
No abstract text is available yet for this article.
November 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27698313/structures-and-physicochemical-properties-of-vortioxetine-salts
#11
Xinbo Zhou, Xiurong Hu, Suxiang Wu, Jiali Ye, Mengying Sun, Jianming Gu, Jianrong Zhu, Zhongliang Zhang
In the present work, novel salts of the multimodal antidepressant drug vortioxetine (VT) were crystallized with pharmaceutically acceptable acids, aiming to improve the solubility of VT. The acids for VT were selected based on ΔpKa being greater than 2 or 3. Salts of hydrobromic acid (HBr), hydrochloric acid (HCl), p-hydroxybenzoic acid (PHBA), saccharin (SAC) and L-aspartic acid (ASP) were reported. All salts were characterized by single-crystal X-ray diffraction, FT-IR, powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC)...
October 1, 2016: Acta Crystallographica Section B, Structural Science, Crystal Engineering and Materials
https://www.readbyqxmd.com/read/27680105/cost-utility-analysis-of-vortioxetine-versus-agomelatine-bupropion-sr-sertraline-and-venlafaxine-xr-after-treatment-switch-in-major-depressive-disorder-in-finland
#12
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu J Koponen, Katarzyna Kolasa
OBJECTIVES: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the Finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin-norepinephrine reuptake inhibitors. METHODS: A one-year analysis was conducted using a decision tree with a Markov state transition component. The health states were remission, relapse and recovery...
September 29, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27678087/in-vivo-and-in-vitro-effects-of-vortioxetine-on-molecules-associated-with-neuroplasticity
#13
Pirathiv Kugathasan, Jessica Waller, Ligia Westrich, Aicha Abdourahman, Joseph A Tamm, Alan L Pehrson, Elena Dale, Maria Gulinello, Connie Sanchez, Yan Li
Neuroplasticity is fundamental for brain functions, abnormal changes of which are associated with mood disorders and cognitive impairment. Neuroplasticity can be affected by neuroactive medications and by aging. Vortioxetine, a multimodal antidepressant, has shown positive effects on cognitive functions in both pre-clinical and clinical studies. In rodent studies, vortioxetine increases glutamate neurotransmission, promotes dendritic branching and spine maturation, and elevates hippocampal expression of the activity-regulated cytoskeleton-associated protein (Arc/Arg3...
September 26, 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27671324/subchronic-vortioxetine-treatment-but-not-escitalopram-enhances-pyramidal-neuron-activity-in-the-rat-prefrontal-cortex
#14
Maurizio S Riga, Vicent Teruel-Martí, Connie Sánchez, Pau Celada, Francesc Artigas
Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin transporter (SERT) inhibitor. VOR shows pro-cognitive activity in animal models and beneficial effects on cognitive dysfunction in major depressive patients. Here we compared the effects of 14-day treatments with VOR and escitalopram (ESC, selective serotonin reuptake inhibitor) on neuronal activity in the medial prefrontal cortex (mPFC). Ten groups of rats (5 standard, 5 depleted of 5-HT with p-chlorophenylalanine -pCPA-, used as model of cognitive impairment) were fed with control food or with two doses of VOR-containing food...
February 2017: Neuropharmacology
https://www.readbyqxmd.com/read/27572627/effects-of-sertraline-duloxetine-vortioxetine-and-idazoxan-in-the-rat-affective-bias-test
#15
Louise K Refsgaard, Kia Haubro, Darryl S Pickering, Sarah A Stuart, Emma S J Robinson, Jesper T Andreasen
RATIONALE: Affective biases seemingly play a crucial role for the onset and development of depression. Acute treatment with monoamine-based antidepressants positively influences emotional processing, and an early correction of biases likely results in repeated positive experiences that ultimately lead to improved mood. OBJECTIVES: Using two conventional antidepressants, sertraline and duloxetine, we aimed to forward the characterization of a newly developed affective bias test (ABT) for rats...
October 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27525966/the-validity-of-the-different-versions-of-the-hamilton-depression-scale-in-separating-remission-rates-of-placebo-and-antidepressants-in-clinical-trials-of-major-depression
#16
Phillip Raphael Kyle, Ole Michael Lemming, Nina Timmerby, Susan Søndergaard, Kate Andreasson, Per Bech
Our objective was to validate the different versions of the Hamilton Depression Scale (HAM-D) both psychometrically (scalability) and clinically in discriminating antidepressants from placebo in terms of remission rates in an 8-week clinical trial in the acute treatment of major depression. The traditional HAM-D17 version was compared with the shorter HAM-D6 and the longer HAM-D21 or HAM-D24 in a fixed-dose placebo-controlled vortioxetine study. Clinical Global Impression of Severity scores were used to establish standardized cutoff scores for remission across each scale...
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27508501/the-safety-tolerability-and-risks-associated-with-the-use-of-newer-generation-antidepressant-drugs-a-critical-review-of-the-literature
#17
André F Carvalho, Manu S Sharma, André R Brunoni, Eduard Vieta, Giovanni A Fava
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later...
2016: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/27474960/a-meta-analysis-of-the-efficacy-of-vortioxetine-in-patients-with-major-depressive-disorder-mdd-and-high-levels-of-anxiety-symptoms
#18
David S Baldwin, Ioana Florea, Paula L Jacobsen, Wei Zhong, George G Nomikos
BACKGROUND: Coexisting anxiety is common in major depressive disorder (MDD) and more difficult to treat than depression without anxiety. This analysis assessed the efficacy, safety, and tolerability of vortioxetine in MDD patients with high levels of anxiety (baseline Hamilton Anxiety Rating Scale [HAM-A] total score ≥20). METHODS: Efficacy was assessed using an aggregated, study-level meta-analysis of 10 randomized, placebo-controlled, 6/8-week trials of vortioxetine 5-20mg/day in adults (18-75 years), with a study in elderly patients (≥65 years) analyzed separately...
July 7, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27402279/task-and-treatment-length-dependent-effects-of-vortioxetine-on-scopolamine-induced-cognitive-dysfunction-and-hippocampal-extracellular-acetylcholine-in-rats
#19
Alan L Pehrson, Todd M Hillhouse, Nasser Haddjeri, Renaud Rovera, Joseph H Porter, Arne Mørk, Gennady Smagin, Dekun Song, David Budac, Manuel Cajina, Connie Sanchez
Major depressive disorder (MDD) is a common psychiatric disorder that often features impairments in cognitive function, and these cognitive symptoms can be important determinants of functional ability. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in patients with MDD, including attention, processing speed, executive function, and memory. However, the cause of these effects is unclear, and there are several competing theories on the underlying mechanism, notably including regionally-selective downstream enhancement of glutamate neurotransmission and increased acetylcholine (ACh) neurotransmission...
September 2016: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/27401359/comparative-efficacy-and-acceptability-of-first-generation-and-second-generation-antidepressants-in-the-acute-treatment-of-major-depression-protocol-for-a-network-meta-analysis
#20
Toshi A Furukawa, Georgia Salanti, Lauren Z Atkinson, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Anna Chaimani, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Hissei Imai, Kiyomi Shinohara, Aya Suganuma, Norio Watanabe, Sarah Stockton, John R Geddes, Andrea Cipriani
INTRODUCTION: Many antidepressants are indicated for the treatment of major depression. Two network meta-analyses have provided the most comprehensive assessments to date, accounting for both direct and indirect comparisons; however, these reported conflicting interpretation of results. Here, we present a protocol for a systematic review and network meta-analysis aimed at updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression...
2016: BMJ Open
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"